Drug intelligence / Profile preview

HC122D

Development stage: Preclinical
Lead developer: HebeCell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HC122D is a preclinical-stage cell therapy being developed by HebeCell for the treatment of multiple solid tumors. It is based on a proprietary induced pluripotent stem cell (iPSC) platform to generate next-generation chimeric antigen receptor natural killer (nCAR-NK) cells. This off-the-shelf approach is designed to target solid tumors by combining the specificity of an engineered CAR with the innate anti-tumor activity of NK cells, potentially offering a more scalable alternative to autologous cell therapies.

Beyond the preview

Go deeper on HC122D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC122D.

Explore the full profile